Mplx stock price has remained resilient despite crude

MPLX stock price has remained resilient despite crude oil volatility, hovering near the $41 mark, with analysts projecting potential upside toward $43–$44 over the next month if commodity spreads persist. While Pfizer's headed for significant losses due to patent expirations, it used the profits its COVID products generated to acquire new revenue streams. In 2024, regulators granted more than a dozen approvals to Pfizer drugs. It also has a big late-stage development pipeline that produced eight phase 3 clinical trial readouts last year. While pointing to MPLX’s recent acquisition of Northwind as a positive catalyst, Stifel warned that it might take 12 to 18 months for the full advantages to become apparent when growth projects begin. MPLX stock price’s recent uptick is backed by optimistic forward EBITDA estimates, with consensus forecasting mid-single-digit annual growth through